Specialist Hematopathology Prometric & Licensing Exam 2026: Complete Syllabus, Passing Marks and Study Guide (DHA, MOHAP, DOH, SCFHS, Oman, Qatar DHP, NHRA, Kuwait MOH)

If you are a physician trained in Hematopathology or laboratory hematology and plan to practise in the Middle East, your licensing pathway will depend on how the target regulator classifies your qualification. The title may sit under Clinical Pathology, Hematological Pathology, Laboratory Medicine/Hematology or a broader physician hematology pathway, so the assigned examination is not identical across Gulf authorities.

This guide covers the major Middle East health authorities and explains the eligibility requirements, exam format, syllabus, reference books and licensing pathways relevant to Specialist Hematopathology candidates.

1. What is the Specialist Hematopathology Exam?

The Specialist Hematopathology licensing or classification assessment evaluates advanced competence in benign and malignant blood disorders, hematolymphoid diagnosis, coagulation and thrombosis, transfusion medicine, bone marrow transplantation, hematologic emergencies and laboratory-clinical integration. Depending on the regulator, the title may be assessed through a dedicated Hematopathology CBT, a broader Hematology and Oncology or Clinical Pathology exam, or qualification-based specialist review.

Question type: Where a computer-based Hematopathology or mapped hematology examination is required, questions are predominantly single-best-answer multiple-choice questions. The exact title and blueprint depend on the regulator.

Language: English. Prometric licensing examinations covered by this guide are conducted in English.

Delivery: Mainly computer-based testing through Prometric or another authority-approved platform where an examination is assigned. Some regulators may instead use qualification review, board recognition or another specialist assessment pathway.

Result: Reporting varies by authority. The UAE guideline used across DHA, MOHAP and DOH publishes a fixed pass percentage. Other regulators may apply a different exam title, score standard or qualification-based classification.

Attempts: Authority-specific. The UAE Unified PQR provides three examination attempts across the UAE Authorities, with limited additional-attempt provisions. Other jurisdictions apply their own classification and examination policies.

2. Middle East Health Authorities and Regulatory Pathways for Specialist Hematopathology

Hematopathology is not labelled identically across the region. The UAE explicitly recognises Hematopathology as a sub-specialty under Clinical Pathology, Saudi Arabia recognises Hematological Pathology as a physician specialty, Qatar publishes a Laboratory Medicine/Hematology scope, and Oman has a Hematopathology training programme but no current standalone occupational-classification exam. The table below summarises the practical licensing position.

3. Specialist Hematopathology Passing Marks and Exam Format

Specialist Hematopathology examination specifications are not uniform across the Middle East. Across DHA, MOHAP and DOH, the same UAE Specialist Hematopathology specification applies: 100 MCQs in 3 hours with a 60% pass mark. Outside the UAE, candidates must pay close attention to title mapping because regulators may use Hematological Pathology, Clinical Pathology or Hematology and Oncology rather than a dedicated Hematopathology exam.

Note: Qatar DHP lists both Clinical Pathology and Hematology and Oncology as 150-MCQ, 3-hour specialist exams with a 65% pass mark, but does not list a standalone Hematopathology examination. Its registration resources separately publish a Laboratory Medicine/Hematology physician scope. Applicants should therefore wait for DHP to confirm the exact title and exam mapping before scheduling. In Saudi Arabia, Hematological Pathology is an official physician specialty and Hematopathology is a Saudi Board programme, but the public SCFHS classification-exam catalogue currently lists Hematology and Oncology rather than a separate Hematopathology Prometric exam.

4. Eligibility Criteria for Specialist Hematopathology Candidates

The exact requirements differ by regulator because Hematopathology may be treated as a sub-specialty of Clinical Pathology, a standalone physician specialty or part of a broader laboratory-medicine framework. The qualification must match the title recognised by the target authority; a generic hematology or pathology degree should not be assumed to map automatically to Specialist Hematopathology.

Primary medical qualification: A recognised MBBS, MBChB, MBBCh, MD or equivalent primary medical degree from an accredited institution, with internship where required.

UAE specialty structure: The UAE Unified PQR lists Hematopathology as a sub-specialty under Clinical Pathology. Applicants therefore need a recognised main-specialty and/or sub-specialty pathway that maps to the PQR's Hematopathology title.

UAE experience requirement: For Tier 1 and Tier 2 recognised Specialist qualifications, no post-qualification experience is required after the main or sub-specialty qualification. For Tier 3, UAE nationals and children of Emirati women require no additional experience after the sub-specialty qualification, while non-UAE nationals generally require two years after the sub-specialty qualification.

Saudi classification: SCFHS recognises Hematological Pathology as a physician specialty. Its published scope states that the physician should hold, after the primary medical degree, a specialist qualification or clinical training programme of at least 24 months, subject to SCFHS classification rules and minimum practice requirements.

Qatar title mapping: DHP publishes a Laboratory Medicine/Hematology physician scope, but Hematopathology is not a standalone title in the current specialist qualifying-exam table. The qualification must first be mapped by DHP before the applicable category, experience requirement and exam can be determined.

Professional licence and Good Standing: A valid professional registration/licence and recent Certificate of Good Standing are commonly required. The issuing authority and validity period must meet the target regulator's current rules.

Primary Source Verification: The primary medical degree, pathology/hematopathology qualification, professional licence and claimed experience may require primary-source verification such as DataFlow or another regulator-approved provider.

Training documentation: Regulators may request detailed residency or fellowship certificates, transcripts, curriculum/training duration, bone marrow and laboratory exposure, transfusion-medicine experience, molecular/flow-cytometry exposure and employment records to establish equivalence with the requested title.

Laboratory and clinical scope: Hematopathology practice may combine morphology, flow cytometry, coagulation, transfusion medicine, molecular diagnostics and clinical consultation. The exact reporting authority, blood-bank responsibilities and therapeutic scope depend on the regulator and facility privileges.

Examination exemption is not uniform. UAE authorities apply PQR-based exemption rules, while Saudi Arabia, Qatar, Oman, Bahrain and Kuwait may classify the qualification differently before deciding whether a CBT or another assessment is required. Candidates should obtain the official eligibility or classification decision before booking an examination.

5. Specialist Hematopathology Syllabus and Core Study Areas Across Middle East Health Authorities

The 13 study areas below are the published UAE Specialist Hematopathology domains and are also closely aligned with the current SCFHS Hematology and Oncology classification blueprint. The Saudi blueprint assigns the highest weight to Red Cell Disorders (14%), Acute Leukemia and Myelodysplastic Syndromes (12%), Bleeding Disorders (11%) and Myeloproliferative Disorders (11%), followed by Lymphoproliferative Disorders (10%) and Thrombophilia (9%). Because Hematopathology increasingly relies on integrated morphology, flow cytometry, cytogenetics and molecular genetics, the descriptions below use current diagnostic practice while preserving the regulator's 13-domain structure.

Topic 1: Red Cell Disorders

Approach to anemia using CBC indices, reticulocyte response and peripheral smear; iron deficiency and iron overload; megaloblastic anemia; hemolytic anemia; hereditary membrane and enzyme disorders; hemoglobinopathies including sickle cell disease and thalassemia; polycythemia; and laboratory interpretation of red-cell morphology and hemolysis.

Topic 2: Benign White Cell Disorders

Reactive leukocytosis and leukemoid reactions, neutropenia and agranulocytosis, eosinophilia, lymphocytosis, monocytosis, infection-related and drug-related changes, benign lymphoid/reactive patterns, inherited leukocyte disorders and peripheral-blood morphology that helps distinguish reactive from clonal disease.

Topic 3: Bone Marrow Failure Syndromes

Aplastic anemia, pure red cell aplasia, paroxysmal nocturnal hemoglobinuria, inherited marrow-failure syndromes, pancytopenia, hypocellular marrow differentials, marrow infiltration and fibrosis, diagnostic work-up and indications for immunosuppression, transplantation or specialist escalation.

Topic 4: Bleeding Disorders

Platelet count and function disorders, von Willebrand disease, hemophilia and other coagulation-factor deficiencies, acquired inhibitors, liver-related coagulopathy, DIC, interpretation of PT/INR, aPTT, fibrinogen, D-dimer and mixing studies, and laboratory-clinical assessment of abnormal bleeding.

Topic 5: Thrombophilia

Inherited and acquired thrombophilia, antiphospholipid syndrome, factor V Leiden, prothrombin mutation, antithrombin/protein C/protein S deficiency, appropriate timing and interpretation of thrombophilia testing, venous thromboembolism risk assessment and recognition of testing pitfalls during anticoagulation or acute thrombosis.

Topic 6: Myeloproliferative Disorders

Polycythemia vera, essential thrombocythemia, primary myelofibrosis, chronic myeloid leukemia and other chronic myeloid neoplasms; morphology, marrow findings and molecular markers including JAK2, CALR, MPL and BCR::ABL1; disease classification, prognostic principles and progression to accelerated/blast phase.

Topic 7: Acute Leukemia and Myelodysplastic Syndromes

AML and ALL diagnosis, acute promyelocytic leukemia, blast morphology, cytochemistry where relevant, immunophenotyping by flow cytometry, cytogenetic and molecular abnormalities, measurable residual disease concepts, myelodysplastic neoplasms, current WHO/ICC classification principles and urgent recognition of high-risk presentations.

Topic 8: Lymphoproliferative Disorders and Plasma Cell Dyscrasias

Mature B-cell, T-cell and NK-cell leukemias/lymphomas; Hodgkin lymphoma; chronic lymphocytic leukemia; plasma cell myeloma and related monoclonal gammopathies; integration of morphology, flow cytometry, immunohistochemistry, cytogenetics and molecular testing for diagnosis, classification and risk stratification.

Topic 9: Transfusion Medicine

ABO/Rh and other blood-group systems, pre-transfusion testing, antibody screening and identification, component selection, special blood products, transfusion thresholds, massive transfusion, hemolytic and non-hemolytic transfusion reactions, transfusion-transmitted infection prevention and principles of blood-bank quality and haemovigilance.

Topic 10: Patient Safety

Correct patient and specimen identification, pre-analytical and analytical error prevention, critical-result communication, laboratory quality control and assurance, biosafety, transfusion safety, medication and chemotherapy-related risks, handover, incident reporting and systems-based prevention of diagnostic harm.

Topic 11: Bone Marrow Transplantation and Its Complications

Indications for autologous and allogeneic hematopoietic stem-cell transplantation, donor selection and HLA concepts, conditioning, engraftment, graft-versus-host disease, infection, relapse, graft failure, transplant-associated microangiopathy and other early and late transplantation complications.

Topic 12: Hematologic Emergencies and Complications

Tumor lysis syndrome, leukostasis, hyperviscosity, disseminated intravascular coagulation, severe bleeding, acute hemolysis, febrile neutropenia, sickle-cell crisis, catastrophic transfusion reactions, acute promyelocytic leukemia coagulopathy, oncologic spinal/vascular emergencies and urgent stabilization and referral priorities.

Topic 13: Professionalism and Ethics

Informed consent, confidentiality and genetic information, communication of critical or unexpected diagnoses, disclosure of errors, appropriate test utilization, stewardship of blood products and expensive molecular tests, professional boundaries, conflict of interest, multidisciplinary consultation and ethical responsibilities in laboratory and clinical hematology.

Cross-Authority Focus: UAE and Saudi Hematology Blueprints Overlap Strongly, but the Professional Title May Differ

The UAE Hematopathology guideline and the currently published SCFHS Hematology and Oncology classification blueprint use essentially the same 13 major domains. This makes the UAE syllabus a strong core preparation framework for Saudi physician hematology assessment as well. However, the Saudi professional title and assigned classification exam must still be confirmed in Mumaris+, because SCFHS separately recognises Hematological Pathology and operates a Saudi Board Hematopathology training programme.

6. Recommended Reference Books

The UAE Specialist Hematopathology guideline lists seven core references. Use the latest available editions. Because hematolymphoid classification has changed substantially in recent years, candidates should also supplement the regulator-listed texts with the current WHO classification and current evidence-based diagnostic guidance:

Essential Haematology by A. Victor Hoffbrand, Paul Moss and colleagues, latest edition. Concise core reference for benign and malignant hematology.

Postgraduate Haematology by Hoffbrand, Higgs, Keeling and Mehta, latest edition. Detailed reference for advanced diagnostic and clinical hematology.

Williams Hematology by Kaushansky, Lichtman and colleagues, latest edition. Comprehensive reference covering pathobiology, diagnosis and management of hematologic disease.

Wintrobe's Clinical Hematology by Greer, Arber and colleagues, latest edition. Broad clinical and laboratory hematology reference with strong morphology and diagnostic coverage.

Hematopoietic Stem Cell Transplantation: A Handbook for Clinicians by Wingard and Gastineau, latest edition. Reference for transplant principles and complications.

Professionalism and Ethics, Handbook for Residents, SCFHS, latest edition. Reference for professional conduct and ethical decision-making.

Essentials of Patient Safety, SCFHS, latest edition. Reference for patient-safety principles relevant to laboratory and clinical hematology.

Current classification supplement: WHO Classification of Tumours, Haematolymphoid Tumours, 5th Edition, Volume 11 (IARC, 2024) should be used for contemporary entity definitions, diagnostic criteria and molecular classification. For exam-day preparation, the Specialist Hematopathology MCQ bank on prometricguide.com is designed around the 13-domain cross-authority framework above and includes 2500 plus questions with detailed explanations.

7. Two Ways We Can Help You Get Licensed

Prometric Guide supports Specialist Hematopathology exam preparation across the Middle East, while our sister company Alzantra International supports the UAE licensing process.

For Exam Preparation: Prometric Guide (All Middle East Authorities)

Whether you are targeting DHA, MOHAP, DOH Abu Dhabi, SCFHS Saudi Arabia, OMSB Oman, Qatar DHP, NHRA Bahrain or Kuwait MOH, our MCQ bank provides one broad preparation base across the major Hematopathology and mapped hematology licensing pathways:

2500 plus Specialist Hematopathology MCQs mapped to the 13-topic cross-authority framework.

Detailed explanations with references to Hoffbrand, Williams, Wintrobe, transplant references, current WHO haematolymphoid classification and patient-safety resources.

Free introductory mock tests and topic-wise practice sets.

High-yield coverage of red-cell disorders, coagulation and thrombosis, myeloid and lymphoid neoplasms, transfusion medicine, stem-cell transplantation, hematologic emergencies, safety and professionalism.

Access on any device, unlimited attempts.

Explore the full Specialist Hematopathology exam preparation package on prometricguide.com.

For UAE Licensing Paperwork: Alzantra International (DHA, MOHAP, DOH)

For UAE licensing, Alzantra International supports Hematopathology candidates targeting Dubai, the Northern Emirates and Abu Dhabi with documentation and licensing coordination.

DataFlow / primary-source verification of the medical degree, main-specialty/sub-specialty qualification, professional licence and experience.

DHA Sheryan Specialist Hematopathology application and assessment coordination for Dubai.

MOHAP specialist evaluation and licensing application for the Northern Emirates.

DOH Abu Dhabi Specialist Hematopathology application through TAMM.

Medical degree, Clinical Pathology/Hematopathology training, transcripts, experience and supporting-document preparation guidance.

Eligibility submission, tracking and follow-up.

CBT or additional assessment coordination where required.

Specialist licence activation and UAE facility-credentialing support.

Contact Alzantra International at www.alzantra.ae or [email protected] for UAE licensing support. For SCFHS/Saudi Arabia, Oman, Qatar DHP, NHRA Bahrain and Kuwait MOH, use the relevant regulator's official pathway.

8. Frequently Asked Questions

What is the passing score for Specialist Hematopathology?

For DHA, MOHAP and DOH, Specialist Hematopathology is 100 MCQs in 3 hours with a 60% pass mark. SCFHS does not currently list a separate Hematopathology Prometric test in its public classification catalogue; if a candidate is assigned the Hematology and Oncology classification exam, that blueprint uses 65% for Registrar and 70% for Senior Registrar. Qatar's Clinical Pathology and Hematology and Oncology specialist exams are both listed at 65%, but the exact Hematopathology mapping must be confirmed by DHP.

What qualification is required for Specialist Hematopathology?

Eligibility depends on the recognised title pathway. In the UAE, Hematopathology is listed as a sub-specialty under Clinical Pathology, so the applicant's main-specialty and sub-specialty qualifications must map to that structure. Saudi Arabia separately recognises Hematological Pathology as a physician specialty. Other regulators may use Laboratory Medicine/Hematology, Clinical Pathology or another equivalent title, so the exact qualification should be classified before exam booking.

How many questions are in the Specialist Hematopathology exam?

DHA, MOHAP and DOH use the same UAE Hematopathology specification: 100 MCQs in 3 hours. Saudi Arabia has no separately listed public Hematopathology Prometric exam; the Hematology and Oncology classification exam is 200 MCQs in 4 hours if that is the assessment assigned. Qatar does not list Hematopathology separately; its Clinical Pathology and Hematology and Oncology exams are each 150 MCQs in 3 hours.

Which reference books should I use?

The UAE guideline lists Essential Haematology, Postgraduate Haematology, Williams Hematology, Wintrobe's Clinical Hematology, Hematopoietic Stem Cell Transplantation: A Handbook for Clinicians, the SCFHS Professionalism and Ethics handbook and SCFHS Essentials of Patient Safety. For current malignant hematology classification, supplement these with the WHO Classification of Haematolymphoid Tumours, 5th Edition.

Can I complete the exam from my home country?

Often yes when the assigned assessment is delivered through an international Prometric or Pearson VUE network. Availability depends on the regulator, eligibility period and exam title shown during scheduling. Oman currently does not publish a standalone Hematopathology Occupational Classification exam, so its assessment route must be confirmed first.

How does Saudi Arabia classify Hematopathology?

SCFHS recognises Hematological Pathology as a physician specialty and also operates a Saudi Board Hematopathology training programme. However, its current public classification-exam catalogue does not show a separate Hematopathology Prometric test. The closest published physician hematology classification exam is Hematology and Oncology, with 200 MCQs over 4 hours and 65%/70% Registrar/Senior Registrar thresholds. Applicants should follow the specific assessment assigned in Mumaris+.

How many attempts do I get?

Attempt rules depend on the authority and the exact exam assigned. UAE examinations follow the Unified PQR framework of three attempts across the UAE Authorities, with limited provisions for additional attempts. Bahrain permits four initial licensure-exam attempts within three years. For Saudi Arabia, Qatar, Oman and Kuwait, follow the attempt policy attached to the actual classification or eligibility decision.

Does every Middle East authority use the same Specialist Hematopathology exam?

No. DHA, MOHAP and DOH use the same UAE Hematopathology specification. Saudi Arabia recognises Hematological Pathology but does not currently show a separate Hematopathology Prometric classification test. Qatar has Laboratory Medicine/Hematology as a physician scope but may map the assessment to Clinical Pathology or Hematology and Oncology. Oman has Hematopathology training but no current standalone Occupational Classification exam.

Is Hematopathology the same as clinical Hematology or Hematology and Oncology?

Not necessarily. Hematopathology focuses heavily on laboratory and morphologic diagnosis of blood, bone marrow and lymphoid disease and may sit under Clinical Pathology or Laboratory Medicine. Clinical Hematology/Hematology and Oncology includes broader direct patient management and systemic treatment. Regulators may map overlapping qualifications differently, so always apply under the exact title they recognise.

What is the best MCQ bank for Specialist Hematopathology exam preparation?

The Specialist Hematopathology MCQ bank on prometricguide.com includes 2500 plus questions aligned to the 13-topic cross-authority framework, with detailed explanations covering benign hematology, coagulation, hematologic malignancy, transfusion medicine, transplantation, emergencies, patient safety and professional practice.

9. Final Thoughts

Specialist Hematopathology is a recognised physician pathway in the UAE and Saudi Arabia, but title naming and examination mapping vary considerably across the Middle East. The UAE offers a dedicated Hematopathology CBT, while Saudi Arabia recognises Hematological Pathology but currently publishes its physician classification CBT under Hematology and Oncology rather than a separate Hematopathology exam. Qatar and Oman require especially careful title confirmation before exam booking.

Prepare around the complete 13-domain hematology framework: red-cell and benign white-cell disorders, marrow failure, bleeding and thrombosis, myeloproliferative neoplasms, acute leukemia/MDS, lymphoproliferative and plasma-cell disorders, transfusion medicine, transplantation, hematologic emergencies, patient safety and professionalism. For malignant hematology, use current WHO/ICC concepts and molecular diagnostic criteria rather than relying only on older textbook classifications.

Prometric Guide supports Specialist Hematopathology candidates preparing across the major Middle East health authorities.